Logo

APLMW

Apollomics, Inc.

APLMW

Apollomics, Inc. • NASDAQ
$0.02 ▲ 12.73% (+0.00)
Market Cap $274.91 M
52w High $0.03
52w Low $0.02
Dividend Yield 0%
P/E 0
Volume 900
Outstanding Shares 14.78B

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q4-2024 $-1.57M ▼ $15.255M ▼ $-18.652M ▲ 1.188K% ▲ $-16.92 ▲ $-15.779M ▲
Q2-2024 $1.768M ▲ $27.079M ▼ $-35.206M ▼ -1.991K% ▲ $-37.56 ▼ $-25.276M ▲
Q4-2023 $333K ▼ $28.664M ▲ $-21.907M ▲ -6.579K% ▲ $-0.24 ▲ $-27.824M ▼
Q2-2023 $488K ▲ $26.17M ▲ $-150.694M ▲ -30.88K% ▼ $-2.56 ▼ $-25.622M ▼
Q4-2022 $-272K $22.308M $-237.394M 87.277K% $-0.001 $-21.461M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q4-2024 $9.766M ▼ $13.098M ▼ $8.234M ▼ $4.864M ▼
Q2-2024 $25.929M ▼ $34.573M ▼ $13.766M ▼ $20.807M ▼
Q4-2023 $37.817M ▼ $55.387M ▼ $14.153M ▼ $41.234M ▼
Q2-2023 $52.616M ▼ $71.378M ▼ $15.681M ▼ $55.697M ▲
Q4-2022 $54.614M $76.475M $524.595M $-448.12M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q4-2024 $-18.652M ▲ $-12.755M ▲ $236K ▼ $-3.652M ▼ $0 $-12.755M ▲
Q2-2024 $-35.206M ▼ $-15.988M ▲ $5.747M ▼ $4.12M ▲ $0 $-16.012M ▲
Q4-2023 $-21.907M ▲ $-18.812M ▲ $21.607M ▲ $3.984M ▼ $0 $-18.812M ▲
Q2-2023 $-150.694M ▲ $-24.397M ▼ $-242K ▼ $17.241M ▲ $0 ▲ $-24.403M ▼
Q4-2022 $-237.394M $-23.098M $5.214M $-141K $-50.7M $-23.128M

Five-Year Company Overview

Income Statement

Income Statement Apollomics is still a development-stage biotech with no product sales, so its income statement is entirely driven by research and corporate costs. Operating losses have been steady over the past several years, reflecting ongoing spending on trials and overhead without any offsetting revenue. Net losses are larger than operating losses, showing the cumulative impact of financing costs and one-time items over time. Overall, the profile is what you would expect from a small, early-stage drug developer: all expense, no commercial income yet, and significant per‑share losses due to the small equity base and reverse split effects.

Balance Sheet

Balance Sheet The balance sheet is very small and relatively thin. Assets are limited and largely made up of cash, with little in the way of physical assets or long‑lived equipment, which fits a lean R&D-focused model. The company reports no debt, which removes the pressure of interest payments but also highlights its dependence on equity and partnerships for funding. Shareholders’ equity has fluctuated between slightly positive and negative, reflecting accumulated losses and recapitalizations; this underlines how fragile the capital base has been. Recent collaboration payments and financing help, but the company still operates with a narrow financial cushion.

Cash Flow

Cash Flow Cash flows show a business that consistently spends cash on operations and generates none from sales. Operating cash outflows have been fairly steady, mirroring ongoing R&D and administrative expenses. Capital spending is minimal, which suggests the company is not investing heavily in facilities or equipment and is instead directing most resources into clinical programs. Free cash flow is therefore negative and closely tracks operating losses. This means Apollomics remains reliant on external capital—deals, equity raises, or similar—to extend its runway, even though recent actions have pushed out its estimated funding horizon.

Competitive Edge

Competitive Edge Apollomics is trying to carve out a space in a very crowded and high-stakes oncology market. Its focus on targeted therapies for specific genetic changes and difficult‑to‑treat cancers can be a competitive advantage, particularly if its drugs show strong results in well‑defined patient groups. The c‑Met inhibitor vebreltinib and the E‑selectin antagonist uproleselan give it differentiated scientific angles compared with more generic cancer approaches. That said, the company faces intense competition from much larger pharma and biotech firms working on overlapping targets and indications, and its smaller size and limited resources make execution, partnering, and trial design critical to maintaining any edge.

Innovation and R&D

Innovation and R&D Innovation is clearly the core of Apollomics’ story. The company has built a broad pipeline around tumor-targeting and immuno‑oncology agents, with programs at multiple stages of development. Vebreltinib stands out due to its selectivity, brain penetration, and potential use across several tumor types, while uproleselan offers a novel way to sensitize leukemia cells to chemotherapy, despite mixed late‑stage results globally. Additional early‑stage candidates, including kinase inhibitors and immune checkpoint antibodies, show that Apollomics is trying to create a platform rather than a single‑asset story. However, the company has already experienced at least one late‑stage setback, and the scientific promise still has to be confirmed by larger, well‑controlled trials, so R&D risk remains high.

Summary

Apollomics is a small, pre‑revenue oncology developer with an ambitious pipeline and a very light financial footprint. The financial statements reflect a typical early biotech profile: steady operating losses, negative cash flow, limited assets, no debt, and a history of recapitalizations and a large reverse split to maintain market listing. On the strategic side, the company has interesting, differentiated drug candidates and some supportive clinical signals, especially for its lead c‑Met inhibitor, plus a partnership that brings in non‑dilutive funding. At the same time, it operates in a fiercely competitive field, with tight resources, past clinical disappointments, and high dependence on future trial outcomes and additional financing. Overall, the picture is one of high scientific potential combined with substantial financial and execution uncertainty.

NEWS

November 19, 2025 · 5:38 PM UTC

Apollomics Announces Settlement of Cayman Litigation

Read more

November 17, 2025 · 11:00 PM UTC

Apollomics Announces Changes to its Board of Directors and Composition of Committees

Read more

October 15, 2025 · 2:36 PM UTC

Apollomics Announces Continued Listing on The Nasdaq Stock Market Following Hearing Cancellation

Read more

October 14, 2025 · 4:05 PM UTC

Nasdaq Resumes Trading in Apollomics Inc.

Read more

October 13, 2025 · 9:22 PM UTC

Apollomics, Inc. Company Operational Continuity Update

Read more